Active pharmacovigilance of the seasonal trivalent influenza vaccine produced by Instituto Butantan: A prospective cohort study of five target groups.

Tazio VanniBeatriz da Costa ThoméMayra Martho Moura de OliveiraVera Lúcia GattásMaria da Graça SalomãoMarcelo Eiji KoikeMaria Beatriz Bastos LucchesiPatrícia Emília BragaRoberta de Oliveira PiorelliJuliana Yukari Koidara ViscondiGabriella MondiniAnderson da SilvaHeloísa Maximo EspínolaJoane do Prado SantosSamanta Hosokawa Dias de Nóvoa RochaLily Yin WeckxOlga MenangMuriel SoquetAlexander Roberto Precioso

Published in: PloS one (2021)

The results from the two studies confirmed that the 2017 and 2018 seasonal trivalent influenza vaccines produced by Instituto Butantan were safe and that active pharmacovigilance studies should be considered, when it is feasible, as an important initiative to monitor vaccine safety in the post-marketing period.

Keyphrases

adverse drug
case control
drug induced
quality improvement
emergency department